Billy Dunn, who presided over the polarizing approval of the Alzheimer’s disease treatment Aduhelm, is leaving the Food and Drug Administration after more than 15 years at the agency, STAT has learned.
Dunn, 53, is retiring from the agency to “explore other opportunities,” according to an internal FDA email sent Monday. Dunn notified agency officials Friday, according to a person with knowledge of the situation.
“It is with regret that I announce the departure of Dr. Billy Dunn, director of the office of neuroscience,” Peter Stein, head of the FDA’s office of new drugs, wrote in an email to colleagues. “After a long and highly productive career in public service, Billy has decided to retire from FDA and explore other opportunities while continuing his focus on improving the lives of patients with neurological diseases.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect